Skip to main content

Advertisement

Table 3 Distribution of metastases at baseline and most recent follow-up

From: Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST

Location of metastases # of patients (%)a at baseline # of patients (%)a at most recent follow-up
Lung 9 (56.3) 10 (62.5)
Liver 9 (56.3) 9 (56.3)
Lymph nodes 2 (12.5) 5 (31.3)
Subcutaneous 4 (25.0) 4 (25.0)
Other soft tissue 5 (31.3) 6 (37.5)
Total # of patients with metastases 16 (100.0) 16 (100.0)
  1. aPercentages based on 16 patients found to have metastases. Eleven patients (68.8 %) had bone metastases, which were not evaluable by volumetric segmentation. Values were obtained by retrospective analysis; thus two patients with unnoticeable metastatic disease at baseline are included